Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Centorrino, F. Articles by Baldessarini, R. J. Search for Related Content PubMed Citation Articles by Centorrino, F. Articles by Baldessarini, R. J. Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders

Multiple Versus Single Antipsychotic Agents for Hospitalized Psychiatric Patients: Case-Control Study of Risks Versus Benefits

OBJECTIVE: Since use of multiple drugs to treat psychiatric patients is increasing, and research on this practice is rare, the authors carried out a retrospective case-control study of multiple versus single antipsychotic treatment in psychiatric inpatients. METHOD: Inpatient treatment groups receiving either antipsychotic monotherapy or polytherapy were matched in terms of age, sex, diagnostic category, and admission clinical ratings (Global Assessment of Functioning [GAF] and Clinical Global Impression [CGI]), which yielded 70 subject pairs. They were compared in terms of total chlorpromazine-equivalent daily dose, changes in total daily dose, length of hospitalization, incidence of adverse effects, and changes in clinical ratings (CGI, GAF, Positive and Negative Syndrome Scale score) between admission and discharge. RESULTS: Initial doses were closely similar at admission for both treatment groups, but the median total final antipsychotic dose was 78% higher for those receiving antipsychotic polytherapy versus monotherapy. Also, median length of stay in the hospital was 55% (8.5 days) longer, and risk of adverse effects was 56% higher with polytherapy, whereas clinical improvement scores were similar (within 11%) for both treatments. CONCLUSIONS: Short-term treatment with multiple antipsychotics was associated with major increases in drug exposure, adverse events, and time in the hospital but with no apparent gain in clinical benefit. These findings require further testing in controlled prospective studies.

This article has been cited by other articles:

				M. Yang, J. C Barner, K. A Lawson, K. L Rascati, J. P Wilson, M L. Crismon, J. Worchel, and C. A Mascarenas Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997-2002 Ann. Pharmacother., September 1, 2008; 42(9): 1229 - 1238. [Abstract] [Full Text] [PDF]

				C. Paton, T. R. E. Barnes, M.-R. Cavanagh, D. Taylor, P. Lelliott, and the POMH-UK project team High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing The British Journal of Psychiatry, June 1, 2008; 192(6): 435 - 439. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Focus, January 1, 2008; 6(2): 212 - 220. [Abstract] [Full Text] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Psychiatr Serv, July 1, 2007; 58(7): 983 - 990. [Abstract] [Full Text] [PDF]

				T. P. Gilmer, C. R. Dolder, D. P. Folsom, W. Mastin, and D. V. Jeste Antipsychotic Polypharmacy Trends Among Medi-Cal Beneficiaries With Schizophrenia in San Diego County, 1999-2004 Psychiatr Serv, July 1, 2007; 58(7): 1007 - 1010. [Abstract] [Full Text] [PDF]

				J. P. Babbar Polypharmacy and Adverse Drug Reactions Psychiatr Serv, July 1, 2007; 58(7): 1011 - 1011. [Full Text] [PDF]

				J. A. Kreyenbuhl, M. Valenstein, J. F. McCarthy, D. Ganoczy, and F. C. Blow Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns Psychiatr Serv, April 1, 2007; 58(4): 489 - 495. [Abstract] [Full Text] [PDF]

				R. J. Baldessarini, L. Leahy, S. Arcona, D. Gause, W. Zhang, and J. Hennen Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders Psychiatr Serv, January 1, 2007; 58(1): 85 - 91. [Abstract] [Full Text] [PDF]

				W. G. Honer, A. E. Thornton, E. Y.H. Chen, R. C.K. Chan, J. O.Y. Wong, A. Bergmann, P. Falkai, E. Pomarol-Clotet, P. J. McKenna, E. Stip, et al. Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia N. Engl. J. Med., February 2, 2006; 354(5): 472 - 482. [Abstract] [Full Text] [PDF]

				H. Ito, A. Koyama, and T. Higuchi Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription The British Journal of Psychiatry, September 1, 2005; 187(3): 243 - 247. [Abstract] [Full Text] [PDF]

				L. CITROME, A. JAFFE, and J. LEVINE Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients Am J Psychiatry, March 1, 2005; 162(3): 631 - 631. [Full Text] [PDF]

				J. Rosack Polypharmacy: Too Much Of a Good Thing? Psychiatr News, May 7, 2004; 39(9): 1 - 75. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us